Friedman M - Search Results

1

Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease.

Rennard SI, Anderson W, ZuWallack R, Broughton J, Bailey W, Friedman M, Wisniewski M, Rickard K. Rennard SI, et al. Among authors: friedman m. Am J Respir Crit Care Med. 2001 Apr;163(5):1087-92. doi: 10.1164/ajrccm.163.5.9903053. Am J Respir Crit Care Med. 2001. PMID: 11316640 Clinical Trial.

2

Extended therapy with ipratropium is associated with improved lung function in patients with COPD. A retrospective analysis of data from seven clinical trials.

Rennard SI, Serby CW, Ghafouri M, Johnson PA, Friedman M. Rennard SI, et al. Among authors: friedman m. Chest. 1996 Jul;110(1):62-70. doi: 10.1378/chest.110.1.62. Chest. 1996. PMID: 8681667

3

Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease.

Littner MR, Ilowite JS, Tashkin DP, Friedman M, Serby CW, Menjoge SS, Witek TJ Jr. Littner MR, et al. Among authors: friedman m. Am J Respir Crit Care Med. 2000 Apr;161(4 Pt 1):1136-42. doi: 10.1164/ajrccm.161.4.9903044. Am J Respir Crit Care Med. 2000. PMID: 10764302 Clinical Trial.

4

Combined bronchodilator therapy in the management of chronic obstructive pulmonary disease.

Friedman M. Friedman M. Respirology. 1997;2 Suppl 1:S19-23. Respirology. 1997. PMID: 9400691 Review.

5

A multicenter study of nebulized bronchodilator solutions in chronic obstructive pulmonary disease.

Friedman M. Friedman M. Am J Med. 1996 Jan 29;100(1A):30S-39S. doi: 10.1016/s0002-9343(96)80061-1. Am J Med. 1996. PMID: 8610715 Clinical Trial.

6

Formoterol therapy for chronic obstructive pulmonary disease: a review of the literature.

Friedman M, Della Cioppa G, Kottakis J. Friedman M, et al. Pharmacotherapy. 2002 Sep;22(9):1129-39. doi: 10.1592/phco.22.13.1129.33523. Pharmacotherapy. 2002. PMID: 12222549 Review.

7

Economic burden of chronic obstructive pulmonary disease. Impact of new treatment options.

Friedman M, Hilleman DE. Friedman M, et al. Pharmacoeconomics. 2001;19(3):245-54. doi: 10.2165/00019053-200119030-00003. Pharmacoeconomics. 2001. PMID: 11303413 Review.

8

Pharmacoeconomic evaluation of COPD.

Hilleman DE, Dewan N, Malesker M, Friedman M. Hilleman DE, et al. Among authors: friedman m. Chest. 2000 Nov;118(5):1278-85. doi: 10.1378/chest.118.5.1278. Chest. 2000. PMID: 11083675

9

Formoterol and ipratropium in COPD.

Friedman M. Friedman M. Am J Respir Crit Care Med. 2003 Jun 1;167(11):1579. doi: 10.1164/ajrccm.167.11.958. Am J Respir Crit Care Med. 2003. PMID: 12770860 No abstract available.

10

Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD.

Friedman M, Serby CW, Menjoge SS, Wilson JD, Hilleman DE, Witek TJ Jr. Friedman M, et al. Chest. 1999 Mar;115(3):635-41. doi: 10.1378/chest.115.3.635. Chest. 1999. PMID: 10084468 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

3,643 results

Search Page